Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...
The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to Eli Lilly’s (LLY) tirzepatide. Share price reaction ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
Novo Nordisk A/S Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week ...
Denmark-headquartered Novo Nordisk, a leading global healthcare company founded in 1923 to drive change to defeat serious chronic diseases built upon our heritage in diabetes, announced headline ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback